These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 8400272

  • 1. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.
    Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A.
    Blood; 1993 Oct 01; 82(7):2235-8. PubMed ID: 8400272
    [Abstract] [Full Text] [Related]

  • 2. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.
    Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM.
    Blood; 1998 Mar 01; 91(5):1810-9. PubMed ID: 9473250
    [Abstract] [Full Text] [Related]

  • 3. Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy.
    Zhang MJ, Baccarani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giralt S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, Horowitz MM.
    Br J Haematol; 1997 Oct 01; 99(1):23-9. PubMed ID: 9359497
    [Abstract] [Full Text] [Related]

  • 4. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.
    Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, Horowitz MM.
    Blood; 2000 Jan 15; 95(2):410-5. PubMed ID: 10627443
    [Abstract] [Full Text] [Related]

  • 5. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome.
    Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW.
    Blood; 1995 May 15; 85(10):2981-90. PubMed ID: 7742558
    [Abstract] [Full Text] [Related]

  • 6. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
    Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B.
    Blood; 1994 Dec 15; 84(12):4064-77. PubMed ID: 7994025
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
    Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, Bordigoni P, Ifrah N, Dauriac C, Cahn JY.
    Blood; 1995 Apr 15; 85(8):2263-8. PubMed ID: 7718899
    [Abstract] [Full Text] [Related]

  • 8. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A, Bureo E, Ortega JJ, Richard C, Olivé T, Maldonado MS, Madero L, Díaz MA.
    Haematologica; 1998 Nov 15; 83(11):981-4. PubMed ID: 9864916
    [Abstract] [Full Text] [Related]

  • 9. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.
    Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A.
    Blood; 1993 Jul 15; 82(2):398-407. PubMed ID: 8329700
    [Abstract] [Full Text] [Related]

  • 10. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
    Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):509-16. PubMed ID: 8298562
    [Abstract] [Full Text] [Related]

  • 11. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R, Heimpel H, Kolb HJ, Heinze B, Hochhaus A, Griesshammer M, Pralle H, Queisser WP, Essers U, Falge C.
    Leuk Lymphoma; 1993 Nov 15; 11 Suppl 1():159-68. PubMed ID: 8251890
    [Abstract] [Full Text] [Related]

  • 12. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.
    Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM.
    J Clin Oncol; 1997 May 15; 15(5):1767-77. PubMed ID: 9164184
    [Abstract] [Full Text] [Related]

  • 13. Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase.
    Copelan EA, Grever MR, Kapoor N, Tutschka PJ.
    Br J Haematol; 1989 Apr 15; 71(4):487-91. PubMed ID: 2653406
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure.
    Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queisser W, Tobler A.
    Blood; 1999 Dec 01; 94(11):3668-77. PubMed ID: 10572078
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M.
    Semin Oncol; 1994 Dec 01; 21(6 Suppl 14):8-13. PubMed ID: 7992099
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, de Witte T, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A.
    Bone Marrow Transplant; 1997 Oct 01; 20(7):553-60. PubMed ID: 9337056
    [Abstract] [Full Text] [Related]

  • 20. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.
    Blood; 1999 Jul 15; 94(2):434-41. PubMed ID: 10397710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.